AAA
ADCT icon

Affinity Asset Advisors’s ADC Therapeutics ADCT Stock Holding History

Affinity Asset Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-474,744
Closed -$1.5M – 87
2024
Q2 		$1.5M Buy
+474,744
New +$1.89M 0.17% 73
2024
Q1 		– Sell
-1,013,540
Closed -$1.68M – 96
2023
Q4 		$1.68M Sell
1,013,540
-86,460
-8% -$79.8K 0.31% 58
2023
Q3 		$987K Buy
1,100,000
+500,000
+83% +$665K 0.28% 60
2023
Q2 		$1.29M Hold
600,000
– – 0.45% 43
2023
Q1 		$1.17M Buy
+600,000
New +$2.21M 0.39% 53

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Affinity Asset Advisors's ADCT Position: Q3 2024 in Review

Affinity Asset Advisors sold out of ADC Therapeutics (ADCT) in Q3 2024, closing a stake of 474,744 shares — an estimated $1.5M sold.

Affinity Asset Advisors first reported a position in ADCT in Q1 2023 and held it in 5 quarters. The position peaked at $1.68M in Q4 2023. 77 funds tracked by Wall St. Rank hold ADCT as of Q3 2024.

  • Affinity Asset Advisors reported no remaining ADC Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 474,744 ADC Therapeutics shares in Q3 2024, an estimated $1.5M.
  • Affinity Asset Advisors first reported a position in ADC Therapeutics in Q1 2023 and held it in 5 quarters.
  • Affinity Asset Advisors's ADC Therapeutics position peaked at $1.68M in Q4 2023.
  • 77 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2024.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.